Document:

lidhairexh10_2.htm

Exhibit 10.2

 

Medicine Research and Development Agreement

Party A: Shaanxi Jiali Pharmaceuticals Co., Ltd

Party B: Shaanxi Research Institution of Chinese Traditional Medicines

Location: Xi’an

Date: Dec.10, 2007

 

Under this Agreement, both Party A and Party B have come to terms in accordance with the relevant regulations of Contracts Law to research and develop and apply for production approval for five new “Pediatric cold-curing medicines”: Xiaoer Kechuanling Granule, Xiaoer Fuxiening
Grunules, Xiaoer Digesting Tablet, Xiaoer Kangganjiedu Grannules, and Xiaoer Jianpibuxue Granules.

 

Article 1 the Content of Technology Cooperation

The research and development and the application of the production approval of the five new “Pediatric cold-curing medicines”: Xiaoer Kechuanling Granule, Xiaoer Fuxiening Grunules, Xiaoer Digesting Tablet, Xiaoer Kangganjiedu Grannules, and Xiaoer Jianpibuxue Granules.

Article 2 Fees of R & D Project

 

The initial costs of R&D for five new products is 10 million RMB, and of each one is 2 million RMB, including the fees of R&D, laboratory, clinical trial, drafting application documents other than the related fees caused during medicine approval application process and plant trial-production material fees.

 

Article 3. Technology Service Fees and Payment

 

Both parties agree to the total amount of RMB10,000,000 for Technology Service Fees, which Party A will pay to Party B by way of cash or bank transfer. Schedule of fee payments Party A will pay to Party B are as follows: RMB2,000,000 for start-up funds to be paid within five working days upon execution of this agreement; RMB5,000,000 for
R&D fees to be paid within five working days upon the closing of lab work and the receiving of the acceptance notice; and, the balance of RMB3,000,000 for Project fees to be paid within five working days of receiving the production certificate issued by SFDA.

 

Article 4.The Major Obligations and Rights of Both Parties

 

I. Obligations and Rights of Party A

 

1. Party A shall provide the necessary assistance as required by Party B.  Party A will provide the  relevant certificates, raw materials, package designation and other supplies as required on timely basis and guarantee of quality.

 

2. Party A shall provide the technology service fees on time according to the agreements to guarantee the research work proceeds uninterrupted. Party A will deliver to Party B an invoice for the service fees and related R&D expense. Party A shall pay the fees according to the R&D schedule.

 

3. Party A is responsible for the on-site assessment of the related fees for the medicine administrative examination and for the registration.

 

  

  

  

 

4. Party A is responsible for the fees for the drug batched filing process and for the trial production material.

 

II. Major Obligations and Rights of Party B

 

1. In accordance with the regulations of the Provisions for Drug Registration, Party B is responsible for delivering the research report and the clinical report for the five new “Pediatric cold-curing medicines” to Party A, and to offer the relevant services of drafting
laboratory research and application materials.

 

2. Party B shall be responsible for the preparation and inspection of the three batches of samples.

 

3. Party B is obligated for the revision of application materials free of charge for the duration of the application process.

 

4. Party B will commence work immediately upon the receipt of start-up funds, and is obligated to transfer the new drugs application documents and samples to Party A within one(1) year,and to assist Party A with its filing to Shaanxi Food and Drug Administration.

 

5. Party B is obligated to keep confidential all aspects of the technique work and research entrusted by Party A, without disclosure to others, and no research activities could occur without the prior written authorization of Party A.

 

Article 5 Risks and Responsibilities

 

1. The subject chosen by Party A may fail due to changes in country policies, due to changes to the regulations and laws or other unforeseen reasons.  The losses that may occur shall be assumed by Party A, and the research fees paid by Party A are non-refundable.

 

2. Party A is responsible for failure caused by the changes of Party A’s policies and financial situation or other unforeseen circumstance which are Party A’s responsibility.  Party A will take responsibility, including but not limited to, for violation of Responsibilities, unless there are other agreements in place
agreed upon by both parties. Party B shall not return fees already paid by Party A.

 

3. Party B shall take all of the responsibilities in case this agreement is failed due to the manmade factors or technology or etc. reasons of Party B. Party B shall pay back all of the payments made by Party A.

 

Article 6 Standards and Methods of Acceptance Check

 

1. The quality of preparation samples must satisfy the quality standard stated in the draft of application documents.

 

2. The time of delivering of the whole filling documents is subject to the date agreed upon in this agreement.

 

Article 7 the Violation

 

After the effective date of this agreement, neither party can change the agreement without reasonable a cause.

 

  

  

  

 

1. Party A should be responsible for the fail of application due to by party A’s own causes, Party B shall not pay back all of the payments made by Party A.

 

2. Party A is responsible for the payment of the research and development fees to Party B on time. In addition to current contract fee, Party A shall pay any additional overdue fees equivalent to 1% per day of the current total amount of fees in this agreement. And party B shall deliver the application documents to party A within the term
stipulated in the contract. Party A has the right to deduct late fee equivalent to 1% per day of current total payment.

 

3. Party B shall pay back all of the payments made by Party A, in the case that the failed application is due to a technology error and or reason of party B.

 

Article 8 Settlement of Disputes

 

Any disputes under the Agreement shall be settled through amicable negotiation between the parties hereto. In case no agreement could be reached through negotiation, the disputes shall be submitted to board of arbitration of plaintiff for jurisdiction.

 

Article 9 Early Termination and Changes of Agreement

 

1. If force majeure caused the failure of R&D, with the confirmation between both parties, this agreement will be terminated earlier and be executed in accordance to the provision of Article 4.

 

2. If merger occurs during while this agreement is in affect, the newly formed company shall perform and meet the obligations under this agreement.

 

Article 10 Other Issues

 

1. As the contract provides that “Party B shall pay back all payments made by Party A, in the case that the application fails due to a technology reason and or error of party B.” Therefore, Party B should issue the receipt of the R&D fees paid by Party A to Party B, and Party A shall exchange it for the invoice after the
performance of this contract.

 

2. In case of any other matters, both parties will negotiate on an amicable best efforts basis.

 

3. The agreement is made in duplicate with the same legal affect for each party.

 

4. The agreement effective at the time this agreement is signed and sealed by both parties.

 

 

	Party A: 	 	 	Party B:	 
	Shaanxi Jiali Pharmaceuticals Co., Ltd (Seal)	 	 	Shaanxi Research Institution of Chinese Traditional Medicines (Seal)	 
	 	 	 	 	 
	 	 	 	 	 
	
 
	 	 	
 
	 
	
Signature:    
	 	 	
Signature:
	 
	Contact Number: 	 	 	Contact Number:	 
	Date: 	 	 	Date:lidhairexh10_3.htm

Exhibit 10.3

LID HAIR STUDIOS, INC.

WARRANT CERTIFICATE

Registered Holder:                                                         

Certificate No.                                                                

No. Warrants held:                                                        

 

The Registered Holder is entitled to purchase from Lid Hair Studios, International, Inc., (the Company) one fully paid and non-assessable share of the Company’s common stock  for each Warrant held as stated above at the purchase price of $3.00 per share with a piggyback warrant purchase price of $5.00 per share.  This
Warrant may be exercised in whole or in part at any time prior to 5:00 o'clock P.M., Pacific Time, on September 30, 2011 for the $3.00 share and for the $5.00 piggyback warrant September 30, 2012.

This Warrant Certificate is subject to the terms and conditions set forth in the subscription agreement pursuant to which the Warrant was purchased.  A copy of such terms and conditions may be obtained from the Company upon request.

 

 

____________________________

Eric Anderson , President

Dated:                                                      

PURCHASE FORM

The undersigned hereby irrevocably elects to exercise this Warrant Certificate to the extent of ____ shares of the common stock, and hereby makes payment of

$____________                                

($5.00 x # OF WARRANTS EXERCISED) in payment of the purchase price thereof.

INSTRUCTIONS FOR REGISTRATION OF STOCK

Name & Address:    _______________________________

_______________________________

_______________________________

_______________________________

 

 

 

By:                              _______________________________

Signature of Record Holder

Dated:lidhairexh10_4.htm

Exhibit 10.4 

 

 

LEASE CONTRACT

 

Lessor: Shaanxi Hengwei Property Management Co., Ltd

 

Lessee:  Shaanxi Jiali Pharmaceuticals Co., Ltd.

 

Contract No: CF-2000-0602

 

Contract Address: Nanxin Street 29

 

contract Time: March 10, 2007

 

 

1.  Location of the premises :Xincheng Building, #29 Nanxin Street ,Shaanxi , PRC

Size of the premises   220  square meters (Gross size), quality of the premises    good .

 

2.  Lease term :

 

The lease term will be from March 16,2007     (month)(day)(year) to  March 15, 2012  (month)(day)(year).

 

(Note: the lease term will not be longer than 20 years, and the exceeding part is inefficiency)

 

3.  Rental Amount: the rental will be    RMB27000   per quarter.

 

4.  the payment period and method. The Lessee pays the next installment in the first 10 days of every quarter .

 

5.  Lessee will bear the cost of utilities such as telephone communications, water, electricity, property management fee and gas on time during the lease term.

 

6.  the usage:   handle official business

 

7.  the repair of the premises - the Lessor is responsible for the safeguard.

 

The lessee is responsible for the   telephone,  sanitation service fees, property management fee, water and electricity fees.

 

8.  Does the lessee has the permission of the decoration, additions or alterations, the scope of the decoration, additions or alterations:          ∕

 

When this contract expires, the handle ways of the decoration, additions or alterations:          ∕

 

9.  does the lessor permits lessee to sub-lease the premises? 

 

10.  Earnest money RMB 3000 , and the lessee pays to lessor before the contract signing day.

 

11.  Termination and dissolution of the contract.

 

The lessor has the right to terminate the contract if the lessee has the following actions:

 

 

 

 

 

A. the lessee dose not pay the rental or the delayed payment more than 20 days shall be regarded as a breach of the contract,

 

B. the delayed payment is more than      ∕

 

C. the lessee changes the usage of the premises without the permission of the lessor and related department.

 

D the lessee disobey the contract and does not repair premises result in the damage of the premises and facilities .

 

E. the lessee makes decoration without the permission of the lessor.

 

F. the lessee transfers the premises to others without the permission of the lessor.  

 

The lessee has the right to terminate the contract if the lessor has the following actions.

 

A. the lessor delayed the premise for   ∕   month

 

B. the lessor disobey the contract and does not repair the premise , which made the lessor can’t use the premises.

 

12.  when the lessee return the premises - the contract expire day,

 

13.  breach of the contract - the breaching party pay RMB3000 penalty.

 

(1)  The lessor dose not repair the premise in time or according the demanding, which made the damage to body and property, the lessor is responsible for compensate. 

 

(2)  The lessor should not only pay the delayed fees but also the late fee he does not do the payment.

 

(3)  The lessor is responsible for the damage of the premises if he transfer the premises to others.

 
14.  Both parties will solve the disputes arising from execution of the contract through friendly consultation, or mediation by the related department. In case the agreement cannot be reached, any party may resort to arbitration commission for arbitration over the matter.

 

15.  Other conditions

 

The original contract is invalid

 

 

 

 

 

Lessor: Shaanxi Hengwei Property Management Co., Ltd

 

 

 

 

Lessee:  Shaanxi Jiali Pharmaceuticals Co., Ltd.

 

ID No:610104720804001

 

Tel: 87271818

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

People’s Republic of China

the Certificate of House Ownership

 

 

 

 

 

 

 

 

House Owner - Shaanxi Jiali Pharmaceuticals Co., Ltd.

Location - No. 48 Xibao Road Weibin District

Code - 4530-1

Type of Estate - Stock System

House Status - I Building

Structure - steel and concrete

Total floors - 4 floors

Building Area - 2851.83m2

Issued by - Baoji House Property Administration

Issued Date - Nov. 20, 2001

  

  

  

 

 

People’s Republic of China

the Permit Certificate of State-owned Land Usufruct

 

 

 

 

 

 

 

 

User’s Name - Shaanxi Jiali Pharmaceuticals Co., Ltd

Location - No. 48 Baoguang Road

Purpose - Industry

Type of usage - remises

Expiration Date - June 18, 2050

Area - 5373.2m2

Issued by - Baoji Bureau of Land and Resources

Issued Date - June 3, 2002

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00163-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00163-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00163-of-00352.parquet"}]]